•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
Braveheart Bio to Participate in the Jefferies Global Healthcare Conference in London
Braveheart Bio, Inc. (BRVE) Shareholder/Analyst Call Transcript
Braveheart Bio Shares One-Year Heart Drug Data, Plans New Fixed-Dose Trial
Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026
Braveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026
Braveheart Bio Announces Upcoming Presentations at the American Heart Association Scientific Sessions 2026
Braveheart Bio: In Non-Obstructive HCM, The Therapeutic Window Is The Product
Braveheart Bio (NASDAQ:BRVE) Stock Falls 7.3% – Here’s What Happened
Braveheart Bio to Participate in Stifel Cardiometabolic Forum
Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Braveheart Bio to Participate in Cantor Global Healthcare Conference
Braveheart Bio CFO Acquires 27,777 Shares for $500,000. Is This a Signal BRVE IPO Is a Success?
Braveheart Bio Chairman Chris Viehbacher Buys $1.5M Shares at IPO. What Does This Mean for Investors?
Braveheart Bio CEO Travis Murdoch Buys 83,333 Shares for $1.5 Million. Is This a Buy Signal for Investors?
Braveheart Bio (NASDAQ:BRVE) Director Purchases $999,990.00 in Stock
Braveheart Bio (NASDAQ:BRVE) CFO Buys $499,986.00 in Stock
Braveheart Bio Announces Closing of Upsized Initial Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Braveheart Bio Announces Pricing of Upsized Initial Public Offering
Braveheart Bio Readies $300 Million IPO Plan